This is a preview of subscription content, log in via an institution to check access.
References
Schilling C, Kempe R, Voigt T. Itasetron hydrochloride (DAU 6215Cl): a pharmacokinetically unique 5-HT3 antagonist. Euro J Cancer 1997 Sep; 33 Suppl. 8 (Pt A): 55
Goldschmidt H, Salwender H, Egerer G, et al. Oral itasetron hydrochloride (DAU 6215C1): a long acting, highly bioavailable alternative to ondansetron. 33rd Annual Meeting of the American Society of Clinical Oncology; 1997 May 17–20; Denver, 49
Goldschmidt H, Salwender H, Egerer G, et al. Comparison of oral itasetron with oral ondansetron: results of a double-blind, active-controlled phase II study in chemotherapy-naive patients receiving moderately emetogenic chemotherapy. Anticancer Drugs 1997 Jun; 8: 436–44
Rizzi CA, Prudentino A, Giraldo E. Effects on general behaviour and neurotransmitter functions of a new 5-hydroxytryptamine3 receptor antagonist with potential therapeutic relevance in central nervous system disturbances. Arzneimittel Forschung 1993 Oct; 43: 1033–41
Sagrada A, Turconi M, Bonali P, et al. Antiemetic activity of the new 5-HT3 antagonist DAU 6215 in animal models of cancer chemotherapy and radiation. Cancer Chemother Pharmacol 1991 Oct; 28: 470–4
Salwender H, Egerer G, Kempe R, et al. Oral itasetron hydrochloride (DAU 6215Cl) versus ondansetron: comparable efficacy at a lower dose. Euro J Cancer 1997 Sep; 33 Suppl. 8 (Pt A): 53
Mignot L, Untereiner M, Riviere A, et al. Intravenous itasetron hydrochloride (DAU 6215Cl): an effective alternative to ondansetron. Euro J Cancer 1997 Sep; 33 Suppl. 8 (Pt A): 53
Rights and permissions
About this article
Cite this article
Itasetron. Drugs R&D 2, 243–244 (1999). https://doi.org/10.2165/00126839-199902040-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199902040-00003